Breaking News
February 24, 2018 - UCLA researchers use fluorescent colored proteins to trace origin of heart cells
February 24, 2018 - Home Routines Can Boost a Child’s Readiness for School
February 24, 2018 - FDA Investigating Misuse, Abuse of Gabapentinoids
February 24, 2018 - Scientists find key proteins control risk of osteoarthritis during aging
February 24, 2018 - Izon announce the launch of the qEV2 and qEV10 Exosome Isolation columns
February 24, 2018 - New CSIRO technology can create clean drinking water
February 24, 2018 - Treating sleep-disordered breathing may improve prognosis of heart failure patients
February 24, 2018 - More boys begin school a year late than girls, study finds
February 24, 2018 - Early life exposure to green space could have beneficial effects on cognitive function
February 24, 2018 - Joint Surgery: Aspirin Equals NOAC for Post-Acute VTE Prevention
February 23, 2018 - Scientists identify new marker of arthritis in mice
February 23, 2018 - Beetroot juice supplements may benefit patients with heart failure
February 23, 2018 - New study identifies novel molecular biomarkers of preeclampsia
February 23, 2018 - Researchers discover new link between gut bacteria and obesity
February 23, 2018 - Aimmune Therapeutics’ Pivotal Phase 3 PALISADE Trial of AR101 Meets Primary Endpoint in Patients With Peanut Allergy
February 23, 2018 - Improving Glaucoma Care: Ophthalmology Times
February 23, 2018 - Preventing dementia: The promising, the disappointing and the inconclusive
February 23, 2018 - Duke researchers show how to retrain immune system of peanut-allergy mice
February 23, 2018 - Older males could live longer with light intensity exercise, study suggests
February 23, 2018 - C-sections and gut bacteria linked to childhood obesity risk
February 23, 2018 - Asthmatics have lower degree of DNA methylation in certain immune cells
February 23, 2018 - Uniforms coated with copper nanoparticles could reduce spread of hospital infections
February 23, 2018 - What Not to Do If You Have Asthma and Want to Get Pregnant
February 23, 2018 - Deep brain stimulation may be promising Alzheimer’s treatment
February 23, 2018 - AMSBIO offers new PARPtrap Assay Kit
February 23, 2018 - New study identifies mechanisms to lengthen egg viability in worms
February 23, 2018 - Interventions to improve self-concept could be critical in treating mental health patients
February 23, 2018 - Few minutes of physical activity may lower risk of death in older men, research suggests
February 23, 2018 - Modifications in HIV test enable rapid detection of Zika virus, study states
February 23, 2018 - Could Hackers Target Heart Devices?
February 23, 2018 - Kids’ Mental Health Status Not a Factor in Gun Storage
February 23, 2018 - Revellers ready for festival drug checks, study finds
February 23, 2018 - Stanford researchers explore how enzyme changes and becomes antibiotic-resistant
February 23, 2018 - Scientists decode molecular structure of healthy huntingtin protein
February 23, 2018 - Efficacy of cancer immunotherapy increased by deactivating tumor defence mechanism
February 23, 2018 - Epigenetic changes due to normal aging process linked to cancer risk
February 23, 2018 - Evaluations of Medicaid experiments by states, CMS are weak, GAO says
February 23, 2018 - Biomarkers ID’d for Anesthesia-Related Neural Damage
February 23, 2018 - Study reveals how kidney disease happens
February 23, 2018 - Iron deficiency early in life can have long-lasting consequences for the brain
February 23, 2018 - High protein diet reduces risk of Alzheimer’s disease, research finds
February 23, 2018 - Research extends powerful capabilities of MRI to nanometer scale
February 23, 2018 - Scientists show that cutting-edge technique can efficiently sort nano-sized particles
February 23, 2018 - Dornier’s new laser innovation delivers confidence to glide through deflected scopes
February 23, 2018 - Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson’s Disease Based on Existing Pivotal Clinical Trial Data
February 23, 2018 - Bariatric Surgery Enabled Stopping Diabetes Meds
February 23, 2018 - C-sections and gut bacteria increase risk of childhood obesity
February 23, 2018 - Busting myths about diet and kidney stones
February 23, 2018 - Reformulating vaccines to prevent relapse
February 23, 2018 - Prophylactic use of haloperidol does not reduce delirium burden
February 23, 2018 - Higher prevalence of kidney stones in Southern United States
February 23, 2018 - Lithotripsy has revolutionized modern kidney stone management
February 23, 2018 - Researchers describe important step toward gene therapy for patients with Sandhoff disease
February 23, 2018 - Pain Therapeutics Resubmits New Drug Application for Remoxy ER, an Abuse-Deterrent, Extended-Release Drug Candidate for the Treatment of Chronic Pain
February 23, 2018 - Combo Therapy Highly Active in Untreated RCC
February 23, 2018 - Boosting a key protein to help bones that won’t heal
February 23, 2018 - Advanced method holds promise for substantial improvements in breast cancer diagnosis
February 23, 2018 - MRI and machine learning could predict whether OCD patients will benefit from treatment
February 23, 2018 - Comparing low-fat and low-carb diets finds little difference
February 23, 2018 - FDA Alert: Clarithromycin (Biaxin): Drug Safety Communication
February 23, 2018 - Out of Limbo Into Bomb Scare
February 23, 2018 - Patients who achieve short-term weight loss before bariatric surgery have better outcomes
February 23, 2018 - Beetroot may reduce kidney failure risk after heart x-ray, research reveals
February 23, 2018 - Sleep disruptions in menopause correlated with hot flashes and depression
February 23, 2018 - Scientists discover new treatment approach to curb severe myocarditis
February 23, 2018 - ‘Click chemistry’ approach may improve disease-fighting properties of drugs
February 23, 2018 - NIGHTSEA and EMS team up to offer KEY Award in fluorescence stereo microscopy
February 23, 2018 - Calorie restriction improves intestinal-tissue regeneration after injury
February 23, 2018 - Tobacco Kills, No Matter How It’s Smoked: Study
February 23, 2018 - Q&A: Avindra Nath, MD | Medpage Today
February 23, 2018 - Adherence to sleep apnea treatment affects risk of hospital readmission
February 23, 2018 - Zika virus could be alternative for treatment of aggressive brain cancer
February 23, 2018 - Carbon monoxide enhances efficacy of antibiotic against stomach infection
February 23, 2018 - Study sheds light on biological mechanisms that drive rare pediatric neurogenetic disorders
February 23, 2018 - MSD and Ferring Pharmaceuticals Complete Largest Ever Clinical Trial in Postpartum Haemorrhage
February 23, 2018 - Portable ultrasound can help better detect fluid in the lungs of patients with end-stage kidney disease
February 23, 2018 - Postnova AF2000 system offers reliable characterization of trace metal colloid distribution in the environment
February 23, 2018 - Pioneering study may pave way for effective painkillers to treat neuropathic pain
February 23, 2018 - Research opens up new avenue to minimize risks of transplants
February 22, 2018 - Cabozantinib Active in Advanced Thyroid Cancer
Novel drug combination could enhance immunotherapy responses in patients with lung cancer

Novel drug combination could enhance immunotherapy responses in patients with lung cancer

image_pdfDownload PDFimage_print

Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice.

During the study, published Nov. 30, 2017, in the journal Cell, a team of researchers led by graduate student Michael Topper; research associate Michelle Vaz, Ph.D.; and senior author Stephen B. Baylin, M.D., combined a demethylating drug called 5-azacytidine that chemically reignites some cancer suppressor genes’ ability to operate, with one of three histone deacetylase inhibitor drugs (HDACis). The HDACis work against proteins called histone deacetylases that are involved in processes, such as cell copying and division, and can contribute to cancer development. The combination therapy triggered a chemical cascade that increased the attraction of immune cells to fight tumors and diminished the work of the cancer gene MYC. Based on these findings, investigators have launched a clinical trial of the combination therapy in patients with advanced, nonsmall cell lung cancer.

The development of therapeutic approaches for patients with lung cancer has been a critical medical need, says Baylin, the Virginia and Daniel K. Ludwig Professor of Cancer Research at the Kimmel Cancer Center. While immune checkpoint therapy has been “a tremendous step forward, less than half of patients with lung cancer have benefited to date,” he says.

“In our study, the two-drug epigenetic therapy combination worked exceedingly well, even before putting in the immune checkpoint inhibitors,” Baylin says. “In animal models of lung cancer, the two agents either prevented cancer from emerging or blunted the effects of more aggressive cancers. In both scenarios, a large component of the results involved an increase in immune recognition of the tumors.”

In a series of experiments, researchers studied the combination of 5-azacytidine with the HDACis entinostat, mocetinostat or givinostat in human cancer cell lines and in mouse models of nonsmall cell lung cancers. The treatments were found to alter the tumor microenvironment. In cancer cell lines, 5-azacytidine worked against the cancer gene MYC, causing down regulation of the entire MYC signaling program. Adding the HDACis further depleted MYC, and together the drugs subsequently caused actions that prevented cancer cell proliferation, simultaneously attracted more immune system T cells to the area of the tumor and activated these cells for tumor recognition.

In mouse models, the strongest response was observed when using 5-azacytidine plus givinostat. In one mouse model with a mutant form of nonsmall cell lung cancer, this drug combination given for three months yielded prevention of benign, precursor tumors from becoming cancers and caused 60 percent reduction of overall area of benign tumor appearance in the lungs. By contrast, a group of mice with the same form of lung cancer that were given a mock treatment universally developed large, cancerous lesions in the lungs.

In a second model of mice with established, aggressive, nonsmall cell lung cancer, treatment with an alternating schedule of 5-azacytidine with givinostat and of 5-azacytidine with mocetinostat not only reduced the growth of established, rapidly growing primary tumors but also dramatically reduced metastatic occurrence.

Baylin and colleagues at Memorial Sloan Kettering Cancer Center in New York and Fox Chase Cancer Center in Philadelphia have started a phase I/Ib clinical trial to evaluate if giving mocetinostat with a 5-azacytidinelike drug called guadecitabine can boost immune checkpoint therapy responses in patients with advanced, nonsmall cell lung cancers. The trial is part of the Van Andel Research Institute–Stand Up To Cancer Epigenetics Dream Team and is funded by Merck through the Stand Up To Cancer (SU2C) Catalyst program, an initiative led by SU2C to bring innovative cancer treatments to patients quickly. Matthew Hellmann, M.D., an author on the paper, will lead this trial at Memorial Sloan Kettering, and Jarushka Naidoo, M.B.B.Ch., assistant professor of oncology, will lead at Johns Hopkins.

Source:

https://www.hopkinsmedicine.org/news/media/releases/2_drug_combination_may_boost_immunotherapy_responses_in_lung_cancer_patients

Tagged with:

About author

Related Articles